Hidradenitis Suppurativa Market

• In March 2022, MoonLake had started the Phase II trial of nanobody, sonelokimab for treating moderate-to-severe hidradenitis suppurativa (HS). Sonelokimab has the potential to treat inflammatory diseases by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers that cause inflammation in the body.

• in June 2023, the European Commission approved COSENTYX, an IL-17A monoclonal antibody, for use in adults with active moderate-to-severe hidradenitis suppurativa and an inadequate response to conventional systemic hidradenitis suppurativa therapy.

In this report, the Hidradenitis Suppurativa Market has been segmented by Treatment,Route of Administration, End User and Geography.

Hidradenitis Suppurativa Market, Segmentation by Treatment

The Hidradenitis Suppurativa Market has been segmented by Treatment into Medications, Surgery, Laser Treatment, Photodynamic Therapy (PDT) and Others.

Medications

Medications remain the first-line treatment for managing Hidradenitis Suppurativa (HS), with approximately 60% of patients starting with topical or systemic therapies. Antibiotics, biologics, and corticosteroids help reduce inflammation, control infection, and manage flare-ups. Biologics have shown a 40–50% improvement in moderate to severe cases, highlighting their increasing adoption in clinical practice.

Surgery

Surgical intervention is often necessary for severe or chronic HS, with around 25–30% of patients undergoing procedures such as wide excision or deroofing. Surgery helps remove affected tissue, prevent recurrence, and improve quality of life. Recurrence rates post-surgery vary but have been reported at 10–20%, making careful patient selection essential.

Laser Treatment

Laser therapy is emerging as an effective option, especially for mild to moderate HS, with studies reporting 20–25% of patients receiving laser interventions. Techniques like CO2 laser and Nd:YAG laser target affected follicles, reduce lesion formation, and minimize scarring. Laser treatments are favored for their precision and minimal invasiveness.

Photodynamic Therapy (PDT)

Photodynamic Therapy (PDT) offers a non-invasive alternative, utilized in 10–15% of HS cases, particularly for localized lesions. PDT combines a photosensitizing agent with light exposure to destroy diseased tissue and reduce inflammation. Clinical data suggest significant reduction in lesion size and pain, though repeated sessions may be required for optimal outcomes.

Others

Other treatment approaches, including lifestyle modifications, weight management, and complementary therapies, are applied in less than 10% of cases. These methods aim to reduce triggers and improve patient well-being. While they may not replace medical or surgical options, they serve as important adjuncts in long-term disease management.

Hidradenitis Suppurativa Market, Segmentation by Route of Administration

The Hidradenitis Suppurativa Market has been segmented by Oral, Parenteral, and Others

Oral

Oral medications are the most commonly prescribed treatment for Hidradenitis Suppurativa (HS), with approximately 55–60% of patients receiving them. This category includes antibiotics, retinoids, and hormonal therapies, which help control inflammation, prevent flare-ups, and reduce lesion formation. Oral biologics have shown a 35–45% improvement in moderate to severe cases, making them a cornerstone of long-term management.

Parenteral

Parenteral treatments, including injectable biologics, are used in 30–35% of patients, primarily those with moderate to severe HS unresponsive to oral therapy. These therapies target specific inflammatory pathways to reduce lesion formation and pain. Studies indicate that parenteral biologics can achieve a 50% or higher reduction in disease severity, demonstrating their efficacy in complex cases.

Others

Other treatment options, such as topical therapies, combination regimens, and emerging modalities, are applied in less than 10–15% of cases. These methods help complement primary treatments and may improve patient adherence and outcomes. While not first-line, they play an important role in holistic disease management.

Hidradenitis Suppurativa Market, Segmentation by End User

The Hidradenitis Suppurativa Market has been segmented by End User into Hospitals, Dermatology Clinics, Medical Research Centers, Academic Institutes and Others.

Hospitals

Hospitals represent the largest end-user segment, accounting for approximately 50–55% of Hidradenitis Suppurativa (HS) treatments. They provide access to multidisciplinary care, including dermatology, surgery, and wound management, ensuring comprehensive treatment for severe cases. Hospitals also support advanced procedures such as laser therapy, photodynamic therapy, and surgical excisions, improving overall patient outcomes.

Dermatology Clinics

Dermatology clinics serve as specialized treatment centers, catering to 30–35% of HS patients. These clinics focus on early diagnosis, ongoing management, and preventive therapies. Their expertise in prescribing oral and parenteral medications, along with minor procedural interventions, makes them a preferred option for moderate cases.

Medical Research Centers

Medical research centers contribute to 10–15% of HS patient care, focusing primarily on clinical trials and new treatment development. They are pivotal in exploring biologics, laser technologies, and novel therapies, helping expand treatment options. Insights gained from research centers also drive evidence-based practice in hospitals and clinics.

Academic Institutes

Academic institutes account for roughly 5–10% of the HS market, integrating education, training, and patient care. These institutes often combine research with clinical practice, allowing future dermatologists to learn cutting-edge treatments. Their involvement ensures knowledge dissemination and adoption of innovative therapies across the healthcare ecosystem.

Others

Other end users, including outpatient centers and telemedicine platforms, represent less than 5% of the market. These channels focus on patient convenience, remote monitoring, and long-term disease management. Although smaller in share, they are growing rapidly due to increasing demand for accessible care options.

Hidradenitis Suppurativa Market, Segmentation by Geography

In this report, the Hidradenitis Suppurativa Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Hidradenitis Suppurativa Market Share (%), by Geographical Region

North America

North America dominates the Hidradenitis Suppurativa (HS) market, accounting for approximately 35–40% of global revenue. The region benefits from advanced healthcare infrastructure, high awareness, and widespread access to biologics and surgical treatments. The presence of major pharmaceutical companies and active clinical trials contributes to rapid adoption of innovative therapies.

Europe

Europe holds a significant market share of around 25–30%, driven by strong healthcare systems, government reimbursement policies, and dermatology expertise. Countries such as Germany, France, and the UK lead in research, early diagnosis, and advanced treatment availability. Adoption of biologics and laser therapy is steadily increasing in both hospitals and specialized clinics.

Asia Pacific

Asia Pacific represents about 20–25% of the market, with rapid growth fueled by increasing awareness, improving healthcare infrastructure, and rising patient population. Nations such as Japan, China, and India are witnessing higher adoption of oral and injectable treatments, along with growing interest in minimally invasive procedures. Expanding dermatology clinics and hospitals are enhancing access to care.

Middle East and Africa

The Middle East and Africa region contributes roughly 5–7% of the global market, primarily due to limited awareness and healthcare access. However, growing investment in specialized dermatology centers and medical research is gradually increasing treatment availability. Adoption of standard therapies, including oral and biologic medications, is steadily rising in urban centers.

Latin America

Latin America accounts for approximately 5–8% of the market, driven by urban healthcare infrastructure and increasing patient awareness. Countries such as Brazil and Mexico are seeing a rise in dermatology clinics and hospital-based treatments. Growth is supported by gradual adoption of advanced therapies like biologics and laser treatments.

This report provides an in depth analysis of various factors that impact the dynamics of Global Hidradenitis Suppurativa Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Hidradenitis Suppurativa Market include:

• AbbVie Inc
• Allergan
• AstraZeneca
• GlaxoSmithKline plc.
• Johnson & Johnson Services Inc
• Merck & Co. Inc
• Pfizer Inc

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis